Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
AIM-listed immunotherapy cancer specialist Scancell (SCLP) announced last week that the FDA had posed a few questions regarding its application to run a Phase II combination trial for its SCIB-1 skin cancer compound alongside a checkpoint inhibitor. The market saw this as bad news, and marked the shares down heavily – but I’m not so sure it is all that serious.
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.
Filed under:
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Time left: 02:53:29